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Summary
Objective: Chondrocytes frequently de-differentiate in two-dimensional (2D) culture, especially in the presence of serum. To examine the role
of lysyl oxidase (LOX) induced cross-linking in this phenomenon, the effect of the speciﬁc LOX inhibitor b-aminopropionitrile (BAPN) was
studied in 2D chondrocyte culture.
Design: Chick embryo sternal chondrocytes (both proliferative and hypertrophic, from caudal and cranial zones, respectively) were cultured in
the presence and absence of BAPN. The production and activities of LOX and LOX-like (LOXL) were assessed by enzyme assay and the use
of speciﬁc antibodies. Seventeen batches of serum of different origin were compared. Chondrocyte phenotype was assessed both
morphologically and biochemically, the latter by quantitative analysis of production of radiolabeled cartilage collagens II, IX, X and XI, and the
de-differentiation marker collagen I, for up to 4 weeks in culture.
Results: LOX and LOXL were identiﬁed, by Western blotting and immunoﬂuorescence, and LO activity was measured in the medium, with
both proliferative and hypertrophic chondrocytes. Inhibition of LO activity prevented or delayed chondrocyte de-differentiation, as
characterized by changes in cell shape and synthesis of the ﬁve different collagen types, from the ﬁrst days of culture for up to 4 weeks,
depending on the origin of the serum added to the culture medium.
Conclusion: LO activity may be involved in the control of chondrocyte phenotype, in addition to serum factors. Inhibition of LO activity by BAPN
may be useful for the maintenance of the chondrocyte phenotype in 2D culture. Speciﬁc variations in the relative proportions of collagens II, IX
and XI could be involved in the mechanism underlying these observations.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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In normal cartilage, chondrocytes are known to produce
collagen types II, IX and XI in proportions leading to their
association into thin cartilage-speciﬁc heterotypic ﬁbrils1. A
sub-family of chondrocytes can become hypertrophic and
progressively switch to production of collagen X, charac-
teristic of terminal differentiation2.
In two-dimensional (2D) cell culture, de-differentiation of
chondrocytes in the presence of serum is a well documented
phenomenon. In contrast, in three-dimensional culture, in
agarose gels, the chondrocyte phenotype is maintained3.
Soluble factors present in serum are known to inﬂuence
chondrocyte phenotype4. In addition, many effects of
extracellular matrix variations on cell differentiation have
been reported5,6. In the case of chondrocytes, for example,
we previously showed, in the absence of serum, that de-
differentiation can be induced by culture in three-dimensional
gels of collagen I7, while in gels of cartilage collagens II,
IX and XI, the differentiated phenotype is maintained.
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some soluble factors, can induce the phenotypic modulation
of chondrocytes in culture.
The above observations suggest that the physico-chem-
ical properties of the collagenous matrix might inﬂuence
chondrocyte phenotype. To examine this possibility, we
present here the results of experiments carried out in 2D
culture designed to test the effects of de novo collagen cross-
linking on the maintenance of the chondrocyte phenotype.
Lysyl oxidases (LOXs) initiate covalent cross-linking in
collagens and elastin (and perhaps other substrates) by
oxidizing certain peptidyl lysine/hydroxylysine residues to
peptidyl lysyl/hydroxylysyl aldehydes which then spontane-
ously condense with neighboring amino groups or additional
peptidyl aldehydes8,9. In cartilage, LO activity is known to
promote covalent cross-links in heterotypic collagen II/IX/XI
ﬁbrils10. We show here that inhibition of LO activity using the
speciﬁc inhibitor b-aminopropionitrile (BAPN) can prevent or
delay de-differentiation of chondrocytes for up to 4 weeks of
culture, depending on the origin of the serum present in the
culture medium.
Materials and methods
CELL CULTURES
Seventeen-day-old chick embryo chondrocytes, prepared
by collagenase digestion of caudal and cranial regions of20
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cm2, unless otherwise mentioned, in 35 mm diameter
plastic Petri dishes (P35). The medium was DMEM
supplemented with 25 mg/ml ascorbate, 2 mM glutamine,
100 mg/ml streptomycin, 100 units/ml penicillin and 10%
serum (complete medium). Seventeen different batches of
sera from various origins were compared: 12 fetal calf sera
(FCS) from Biomedia (B1 and B2), Sigma (S1 to S7),
Hyclone (H1) and GIBCO/Life Technologies (G1 and G2);
two neonatal calf sera (NCS) from Sigma (S8) and GIBCO/
Life Technologies (G3); two calf sera (CS) from Hyclone
(H2) and GIBCO/Life Technologies (G4) and one adult
healthy human serum pool (HS). In all, six experiments
were carried out as follows: experiment 1 e FCS B1;
experiment 2 e FCS B2; experiment 3 e FCS S1;
experiment 4 e FCS B2, S2, S3; experiment 5 e FCS S2,
S4, S5, S6, S7 and H1, NCS S8, CS and H2, human adult
serum HS; experiment 6 e FCS S2, S7, G1, G2 and H1,
NCS G3 and CS G4. When FCS was absent, the medium
was supplemented with 1 mM pyruvate and 1 mM cysteine
as protective agents. BAPN was added as indicated at
a concentration of 60 mg/ml. Media including all additives
(purchased from Sigma) were changed every 2e3 days and
cultures were maintained for up to 4 weeks.
COLLAGEN SYNTHESIS
Newly synthesized collagens were metabolically labeled
for 24 h with 1 mCi/ml 14C-proline (285 Ci/mmol: Amersham
International), beginning on days 2, 13, 20 or 27. Culture
media were submitted to pepsinization (pepsin from Serva,
Heidelberg, FRG) as previously described7 at 0.1 mg/ml for
18 h. Cell layers were treated similarly except for pepsin-
ization with 0.3 mg/ml pepsin for 48 h. The amounts of total
newly synthesized pepsin-resistant proteins were deter-
mined by liquid scintillation counting as described7.
Collagen types were analyzed by SDS-polyacrylamide gels
(PAGE) on 4.5e15% gradient gels (in non-reducing
conditions except when mentioned) followed by ﬂuorogra-
phy. Cultures were carried out and analyzed in duplicate.
QUANTITATION OF COLLAGEN TYPES SEPARATED
BY SDS-PAGE
Fluorograms were subjected to densitometry and the
data analyzed using the program Image Quant 4 (Molecular
Dynamics). The linearity of the photographic response of
the ﬂuorograms was veriﬁed and calibrated using a standard
series of radiolabeled collagen chains. Where bands
displayed very low intensities, several ﬂuorograms with
different exposure times were compared to conﬁrm the
absence of these bands, such as that of the a2 type I (a2(I))
collagen chain.
The amounts of each of the ﬁve different collagen types (I,
II, IX, X and XI; each made up of three a chains) were
determined as follows. Collagen X was measured directly
from the area under the a1(X) peak. Collagen I, with two a1(I)
and one a2(I) chains, was determined as three times the area
under the a2(I) peak (the a1(I) chain co-migrates with a1(II)).
Collagen XI was determined as 1.5 times the total area under
the a1(XI) and a2(XI) peaks (the a3(XI) chain co-migrates
with a1(II)). Collagen IX wasmeasured from the peak area of
the major, pepsinized fragment, HMW. Collagen II was
determined from the total area under all collagen peaks
minus the amounts of all other collagens (as determined
above). With some cell-layer extracts from BAPN-free
cultures, a feint band of b11(II) cross-linked chains ofcollagen II was observed just below the HMW band (not
shown), as previously described11. Amounts of each
collagen were then expressed as percentages of total peak
area. Measured dpm values from pepsinized cell-layer
extracts and culture media were then used to convert
percentages of each collagen type into dpm, which were
then added for each collagen type to determine total (cell
layerCmedium) percentages. In this way, results could be
compared between collagen types, expressed as percen-
tages (cell layer, medium and total), and between different
experiments. The average variation between duplicates in
each experiment was found to be about 10%of themeasured
percentage values shown in Figs. 5e7.
It should be noted that, after 14C-proline labeling of
synthesized collagens, the measured intensities for the
different collagen types depend on their prolineC hydrox-
yproline contents. These proportions are known to be rather
similar among the ﬁbrillar collagens I, II and XI, particularly
between different a chains of the same collagen type. In
contrast, due to their smaller triple-helical regions, collagens
IX and X contain less prolineC hydroxyproline than the
ﬁbrillar collagens12. This was particularly so for collagen IX,
where only the HMW fragment was measured, as identiﬁed
by its well characterized differences in migration on SDS-
PAGEwith andwithout reduction11, the LMW fragment being
negligible in most of the ﬂuorograms. No corrections were
made to allow for these differences in prolineC hydroxypro-
line content,whichhasnoeffectwhencomparisonsaremade
with and without BAPN for each collagen type.
ANTIBODIES
Two different polyclonal antibodies were used13e15,
directed against peptides corresponding to residues
228e279 of human preprolysyl oxidase (LOX) and residues
355e416 of human preprolysyl oxidase-like (LOXL). In the
case of LOX, chicken and human forms show 92%
sequence identity in the region used as antigen. No
sequence data are available for chicken LOXL.
IMMUNOFLUORESCENCE STAINING
Cultured cells were seeded at 1.5! 105 cells/cm2. After
2 to 5 days of culture in the presence of FCS with or without
BAPN, non-conﬂuent cell layers were washed with phos-
phate buffered saline (PBS), then ﬁxed in 4% paraformal-
dehyde for 30 min followed by washing with 50 mM NH4Cl/
PBS. Intracellular staining was performed by permeabilizing
cells with 1% Triton X-100 in PBS for 10 min. Each step was
followed by washing with PBS. Treated cell layers were
incubated for 90 min at room temperature with primary
antibodies diluted in PBS/1% serum albumin (BSA) at the
following dilutions: 1:50 for anti-LOX, 1:200 for anti-LOXL.
Samples were then washed thoroughly with PBS, incubated
in cyanine dye-conjugated donkey anti-rabbit IgG (from
Jackson Immuno Research Laboratories), which showed
here no cross reaction with chicken proteins. Samples were
mounted in Dako ﬂuorescent mounting medium and
examined using a Zeiss Universal microscope equipped
for epiﬂuorescence.
PROTEIN EXTRACTION FOR IMMUNOBLOTTING
OF LOX ISOFORMS
Cell seeding was performed at 2! 105 cells/cm2. After 1
or 2 weeks of culture, the medium was discarded and cell
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performed by gentle stirring for 2 h at 4(C with 0.3 ml/P35
of the following lysis buffer: 16 mM Na2HPO4C 6 M
ureaC 0.5% Nonidet NP-40C protease inhibitors (Com-
plete miniCEDTA from Roche), pH 8.0. From each dish,
the lysate was collected, and then the P35 was washed with
3! 0.3 ml 16 mM Na2HPO4 pH 8.0. The combined
volumes (lysateCwash) obtained for each P35 dish were
centrifuged at 20,000g for 20 min at 4(C. Supernatants
were submitted to precipitation with trichloracetic acid at
a ﬁnal concentration of 10% for 20 min at 4(C. Protein
pellets obtained after centrifugation at 10,000g for 10 min
were washed with cold acetone, then dried before adding
SDS-PAGE sample buffer.
ELECTROBLOTTING
Protein extracts, each corresponding to about one P35,
were submitted to electrophoresis in 10% SDS-PAGE.
Electrophoretically resolved bands were then transferred to
PVDF membranes (Immobilon, Millipore Corp.) by electro-
blotting. Proteins were immunodetected using an alkaline
phosphatase conjugate substrate kit (Biorad) at the
following dilutions: 1:100 for anti-LOX, 1:300 for anti-LOXL.
Protein mass markers were purchased from Biorad.
LO ACTIVITY
LO assays were performed with a tritiated elastin
substrate as previously described16. dpm released after
12 h incubation were measured in the presence and
absence of BAPN. Speciﬁc LO activity was measured by
the difference in dpm obtained without and with BAPN.
One day prior to collecting conditioned media for LO
assay, complete culture medium containing FCS was
replaced by serum-free medium supplemented with 1 mM
pyruvate with (day 2) or without (days 6, 13) 1 mM cysteine.
Cysteine and pyruvate were used as protective agents
against oxidative metabolites. Cysteine (1 mM) was found
to partially inhibit LO activity (by approximately 50%) when
added to assays using puriﬁed aortic LOX (not shown).
Cleared conditioned media were maintained at 4(C and
immediately concentrated by ultraﬁltration with 5000 NMWL
cellulose Ultrafree-MC centrifugal ﬁlter devices (Millipore),
then 100 ml aliquots were used for the LO assay.
Results
EXPRESSION OF LOX VARIANTS
Chondrocytes were isolated from both cranial (becoming
hypertrophic after 1 week in culture) and caudal (pro-
liferative) regions of chick embryo sterna. As shown in
Table I, LO activity, as inhibited by the speciﬁc LOX inhibitor
BAPN, was detected on days 3, 7 and 13, with both caudal
and cranial chondrocytes. Compared to day 7 however,
activity on day 14 in the culture medium was diminished,
despite the increased cell number.
Both cranial and caudal chondrocytes expressed at least
two variants of LOX, LOX and LOXL, in the presence and
absence of BAPN, as shown by Western blotting of cell-
layer extracts on day 7 (Fig. 1), using speciﬁc antibodies.
Similar results were obtained on day 14 (data not shown).
The expected molecular weights of active processed forms
of LOX17 and LOXL14 were observed, along with higher
molecular weight bands, which probably correspond topolymerized or unprocessed forms. Overnight incubation at
4(C of both antibodies with the corresponding peptide
antigens adsorbed onto nitrocellulose membranes pre-
vented subsequent detection of protein bands by Western
blotting (data not shown).
By immunoﬂuorescence, both antibodies revealed the
presence, on day 5 of culture, of LOX and LOXL, in both
cranial and caudal chondrocytes. Unlike LOXL, immunos-
taining of LOX was relatively intense in the nucleus, in the
presence or absence of BAPN (Fig. 2), as previously found
with 3T6 myoﬁbroblast-like cells15. In control experiments,
immunostaining was negligible when antibodies were pre-
absorbed on the corresponding antigenic peptides (data not
shown). The presence of BAPN had no obvious effect on
the amounts of each form of LOX present, but only on their
activities.
EFFECT OF BAPN ON CHONDROCYTE MORPHOLOGY
Chondrocyte morphology and biochemically-deﬁned phe-
notype in culture were studied in six different experiments,
using 17 different batches of sera (see Materials and
methods). When cultured at initial densities of
2.0! 105 cells/cm2 for up to 4 weeks in the presence of
10% serum, cells from the cranial region became pro-
gressively hypertrophic in appearance and some lost their
characteristic rounded morphology adopting a spread,
ﬁbroblast-like shape [Fig. 3(C)]. In serum-free medium
supplemented with cysteine and pyruvate, cells multiplied
relatively slowly appearing less hypertrophic but again
becoming progressively ﬁbroblast-like in shape [Fig. 3(D)].
When cultured in the presence of BAPN however, in the
presence or absence of serum, cranial chondrocytes
retained almost exclusively their rounded morphology,
whether hypertrophic or not [Fig. 3(E,F)]. The protective
effect of BAPN on cell morphology was similar with caudal
chondrocytes, which never became hypertrophic (data not
shown).
EFFECT OF BAPN ON BIOCHEMICALLY-DEFINED PHENOTYPE
BAPN was found to prevent changes in chondrocyte
phenotype with respect to synthesis of different collagen
types. As shown in Fig. 4, cranial chondrocytes, when
cultured in the presence of FCS, produced type I collagen in
the culture medium on day 14, in addition to cartilage
collagens II, IX, X and XI. In contrast, in the presence of
both FCS and BAPN, type I collagen production was not
observed. Similar results were obtained with caudal
chondrocytes, which neither became hypertrophic nor
produced collagen X. In contrast, for both caudal and
cranial chondrocytes, using serum-free medium supple-
mented with 1 mM of cysteine and pyruvate as protective
agents, synthesis of collagen I was not observed, and
BAPN did not affect the production of cartilage collagens.
The extent to which BAPN prevented chondrocyte de-
differentiation depended on the duration of culture and the
type/batch of serum used. On day 14, for example, only
some batches of FCS tested led to de-differentiation of
cranial chondrocytes, as measured by production of
collagen I (Fig. 5, middle column), whether in the combined
cell layer plus medium [total, Fig. 5(A)], the cell layer
[Fig. 5(B)] or the medium alone [Fig. 5(C)]. With those cells
that did de-differentiate, however, this effect was completely
prevented by the presence of BAPN, in both cell layer and
medium. In contrast, by days 21 and 28 of culture, almost all
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Lysyl oxidase activities in chondrocyte culture media
Day Cells/sample Original volume of
medium (ml)
before concentration
dpm/100 ml
concentrated
mediumBAPN
dpm/100 ml
concentrated
mediumCBAPN
Average LO
activity of original
medium (dpm/ml)
3 Caudal chondrocytes 0.6 930, 1002 674, 718 481
7 Caudal chondrocytes 1 8158, 8464 5296, 6210 2558
7 Cranial chondrocytes 4 10,932, 10,510 5800, 6536 1138
14 Caudal chondrocytes 3 5010, 5322 4344, 4702 215
14 Cranial chondrocytes 4 5038, 5840 4580, 4618 210
e e e dpmBAPN dpmCBAPN Average LO
activity (dpm)
e Standard LOX from
bovine aorta
e 8540, 8810 4340, 4762 4130
Chondrocytes were cultured in Petri dishes (9.5 cm2) seeded with 2! 106 caudal or cranial cells in the presence of 10% FCS. After a further
24 h incubation at 37(C in serum-free medium, supplemented with cysteine and pyruvate (day 3) or pyruvate alone (days 7, 14), conditioned
medium was concentrated and assayed for LO activity on a 3H-elastin substrate. Samples (100 ml) were measured in duplicate. The original
volume of medium corresponding to each sample, prior to concentration, is indicated. Activity was determined by net dpm measured in the
absence and presence of BAPN, then expressed per ml of medium collected prior to concentration. Two different batches of elastin substrate
were used for the assays on day 3 and days 7/14 media.batches of FCS led to chondrocyte de-differentiation (Fig. 5,
right hand column), as shown by the production of collagen I.
This effect was eliminated or considerably reduced with all
batches of FCS, with the exception of the two obtained from
GIBCO/Life Technologies (G1, G2). This variability in the
onset and extent of de-differentiation suggests the presence
of different amounts of factors in the different batches of
serum that lead, either directly or indirectly, to chondrocyte
de-differentiation.
BAPN also prevented or reduced de-differentiation of
caudal chondrocytes (Fig. 6), in the presence of FCS,
where again the reduction in collagen I synthesis was
dependent on the duration of culture and the batch of serum
used.
The effect of BAPN on cranial chondrocyte de-differen-
tiation in the presence of other types of serum (other than
97
66
45
31
kDa
LOX LOXL
1 2 3 4 1 2 3 4
A B
- + - + - + - +BAPN
Fig. 1. Western blotting analysis reveals similar expression levels of
each lysyl oxidase variant in sternal chondrocytes of both caudal
and cranial origin, in the presence or absence of BAPN. Caudal (1,
2) and cranial (3, 4) chondrocytes were seeded at 2! 105 cells/
cm2, then cultured in the presence of FCS with or without BAPN.
Protein extracts from the cell layer obtained after 1 week in culture
were separated by electrophoresis on 10% SDS-polyacrylamide
gels. After transfer, PVDF membranes were probed using (A) anti-
LOX (228e279) or (B) anti-LOXL (355e416), at dilutions of 1:100
and 1:300, respectively. Arrows indicate the mature forms of LOX
and LOXL.FCS) was less pronounced (see Supplementary material).
With NCS and CS, BAPN only partially inhibited total
collagen I synthesis by cranial chondrocytes on day 14, and
hardly at all on day 21. With the HS, relatively low levels of
collagen I were synthesized, and BAPN had no effect.
In contrast to the results obtained with collagen I, BAPN
was found to have no systematic effect on the percentage
of collagen II production by cranial chondrocytes (see
Supplementary material). BAPN also appeared to have no
A B
C D
caudal cranial
LOXL
LOX
Fig. 2. Indirect immunoﬂuorescence staining of 5-day-old chon-
drocytes in culture reveals the expression of LOX and LOXL by
chondrocytes of both caudal and cranial origin. Cells were plated at
1.5! 105 cells/cm2 and cultured with FCS in the presence or
absence of BAPN. A, B: Anti-LOX (228e279). C, D: Anti-LOXL
(355e416) (respective dilutions: 1:50, 1:200). A, C: Caudal
chondrocytes. B, D: Cranial chondrocytes. Unlike LOXL, LOX
staining was relatively intense in the nuclei of many cells. Bar:
20 mm.
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to be inversely related to that of collagen II in the case of
cranial chondrocytes. This is illustrated in Fig. 7, which
shows the amount of collagens II and X expressed as ratios
of percentages in the presence and absence of BAPN, for
cranial chondrocytes, in different batches of FCS. These
ratios are centred around 1, thus indicating little effect of
BAPN on collagens II and X production. Similar results were
obtained with caudal chondrocytes (see Supplementary
material).
In contrast to the inhibition of collagen I production by
BAPN, and the lack of systematic effect on collagens II and
X, BAPN appeared to increase the percentages of
collagens IX and XI. This is also illustrated in Fig. 7, which
shows a signiﬁcant increase in collagens IX and XI in the
presence of BAPN with cranial chondrocytes, during the
ﬁrst 2 weeks of culture, in the presence of different batches
of FCS, as found in both total [Fig. 7(A)] and cell layer
[Fig. 7(B)] collagens. This indicated a preferential stimula-
tion of collagens IX and XI production by BAPN.
As reported elsewhere18, de-differentiation as assessed
by the above biochemical alterations was minimized when
cells were seeded at high densities (5 to 8! 105 cells/cm2
instead of 2! 105 cells/cm2; data not shown). In addition,
the presence of BAPN was found to slightly increase the
amount of total pepsin-resistant protein produced by these
A B
C D
E F
+FCS -FCS
Day3
-BAPN
Day14
-BAPN
Day14
+BAPN
Fig. 3. Morphological alterations of sternal chondrocytes from the
cranial zone are prevented by the presence of BAPN. Phase
contrast micrographs of cells seeded at 2! 105 cells/cm2 and
cultured for 3 days (A, B) or 2 weeks (CeF) with or without BAPN
and FCS. A, C, E: With FCS. B, D, F: Without FCS. E, F: With
BAPN. A, B, C, D: Without BAPN. At day 3 (A, B), similar
morphologies were seen with BAPN (not shown). Bar: 20 mm.cells (by a factor of 1.31G 0.46 (SD), nZ 50), as measured
by incorporation of 14C-proline, thereby excluding any
possible toxic effects of BAPN.
Discussion
The main observation reported here is that inhibition of
LOX activity by BAPN can prevent or delay de-differentia-
tion of chick embryo chondrocytes in 2D culture. BAPN was
found to preserve the characteristic rounded morphology of
chondrocytes and reduce or eliminate the synthesis of
collagen I for up to 4 weeks in culture.
The onset and extent of chondrocyte de-differentiation
was found to be strongly dependent on the type/batch of
serum used in the cultures. For this reason, we decided to
carry out an exhaustive study of the effects of different sera.
Some batches of FCS were found to induce de-differenti-
ation by day 7 of culture, as detected by the appearance of
collagen I, while with others the effect was not observed
until days 14 or 21. From the onset of de-differentiation, the
percentage of collagen I increased with time. Regardless of
the onset and extent of chondrocyte de-differentiation,
however, inhibition of LO activity by BAPN was found to
either prevent or lower the percentage of collagen I, for all
batches of FCS tested, with the exception of the two
obtained from GIBCO/Life Technologies. With the other
types of serum tested, this effect of BAPN was either much
reduced (NCS or CS) or not seen (adult HS). These data
suggest that different types/batches of serum contain
variable amounts of different factors that lead to phenotypic
modulation, the effects of at least some of which can be
effected by inhibition of LO activity.
1 2 3 4 5 6 7 8
α1(I),α1(II),α3(XI)
α2(I)
α1(X)
HMW
- + - + - + - +
+ + - - + + - -FCS
BAPN
α1(XI)
α2(XI)
- +
+ +
9 10
caudal cranial
Fig. 4. Prevention of collagen I biosynthesis by sternal chondro-
cytes in the presence of BAPN following 2 weeks of culture. Cells
were seeded at 2! 105 cells/cm2, then cultured with or without
FCS, in the presence or absence of BAPN. Radiolabeling of the
cells (24 h) was begun on day 13. On day 14, culture media were
collected from caudal (lanes 1e4) or cranial (lanes 5e8) cells then
subjected to limited digestion with pepsin, or cell-layer pepsin
extracts from cranial cells (lanes 9e10), were analyzed by SDS-
PAGE (in non-reducing conditions) and ﬂuorography. Migration
positions of different collagen chains are indicated. HMW denotes
the high molecular weight pepsin-resistant fragment of collagen IX.
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Fig. 5. Effects of long-term added BAPN on collagen I production by sternal chondrocytes of cranial origin in the presence of different batches
of FCS. Cells were seeded at 2! 105 cells/cm2, then cultured with FCS (from 12 different batches), in the presence or absence of 60 mg/ml
BAPN. Radiolabeling of the cells (24 h) was begun on days 2, 6, 13, 20 and 27. Pepsinized culture media and cell-layer extracts were
analyzed by SDS-PAGE and ﬂuorography, then collagen I, expressed as a percentage of total collagens, was quantitated by densitometry. (A)
Total, i.e., cell layerCmedium, (B) cell layer, (C) medium. Batches of serum are indicated in color, as follows: B1, B1#, B2, B2# (purple); G1,
G2 (blue); H1 (green); S1 (orange), S2eS7 (black). All points shown represent the average of two separate experiments performed at the
same time. Experiments indicated by a prime (e.g., B1#) refer to those carried out on a different occasion to those previously performed using
a particular batch of serum. Overlapping points are offset horizontally.Four possible mechanisms can be proposed for the
observed effects of LOX on the modulation of chondrocyte
phenotype:
(i) The extent of cross-linking, initiated by LOXs, may
alter the mechanical properties of the extracellular
matrix and, consequently, cellular responses to
mechanical stimuli involving integrin receptors19,20.
This may also account for the observation that
ascorbate leads to enhanced chondrocyte de-differ-
entiation21, since the extent of prolyl hydroxylation,determined by ascorbate, would inﬂuence the stability
and hence mechanical properties of the ﬁbrils.
(ii) Several different types of cell surface collagen
receptors, acting either individually or synergistically
across different signaling pathways22,23, might be
involved in the control of the differentiated phenotype
by the structure of the matrix, through differential
binding to different ﬁbrillar forms of collagen cross-
linked to different extents. These receptors include: (1)
b1 integrins (native collagens) or bv integrin (dena-
tured collagens)7,24, (2) discoidin domain receptors
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Fig. 6. Effects of long-term added BAPN on production of collagen type I by sternal chondrocytes of caudal origin in the presence of different
batches of FCS. Cells were seeded at 2! 105 cells/cm2, then cultured with FCS (of four different origins), in the presence or absence of
60 mg/ml BAPN. Radiolabeling of the cells (24 h) was begun on days 2, 6, 13 and 20. Pepsinized culture media and cell-layer extracts were
analyzed by SDS-PAGE and ﬂuorography, then total collagen type I (cell layerCmedium), expressed as a percentage of total collagens, was
quantitated by densitometry. Overlapping points are offset horizontally.(DDRs)25, (3) transmembrane heparan sulphate pro-
teoglycans, e.g., syndecans26, (4) transmembrane
chondroitin sulphate proteoglycans, e.g., CD4427 and
NG228 and (5) annexin V/anchorin C II29. It should be
noted that other forms of cross-linking activity, not
sensitive to BAPN, could also modulate matrix
structure, and thereby cell phenotype, which might
account for the reduced effect of BAPN after 3 or 4
weeks in culture. Tissue transglutaminases30,31, for
example, are known to be present in the calcifying
growth plate of cartilage during late differentiation.
(iii) Several soluble factors present in serum, including
BMPs, FGF, IGF and TGF-b, can directly modulate the
chondrocyte phenotype2,32. Furthermore,
TGF-b33, FGF234 and also PDGF35 and TNF36 can
modulate LOX synthesis and/or activity, in different
cell lines, while oxidation of lysine residues by LOX
can inhibit bFGF activity37. Thus, in addition to their
general anabolic effects on protein synthesis, serum
factors might act synergistically with LOXs to regulate
chondrocyte phenotype. Differences in the amounts of
such factors would account for the observed variation
in the timing and extent of de-differentiation between
FCS and other types of serum. The nature, amounts
and synergistic effects of the speciﬁc factors involved
remain to be determined.
(iv) Finally, the demonstration of LOX in an active BAPN-
dependent form within the cell nucleus38 and associ-
ated with the cytoskeleton39 strongly suggests possi-
ble intracellular targets of the enzyme, such as
histones40. In this regard, we note that LOX was
observed here inside the nuclei of the sternal chick
embryo chondrocytes.
Whichever mechanisms are involved, it is clear that
inhibition of LO activity, rather than any changes in
expression of the different forms of LOX, is required for
the observed effects on chondrocyte differentiation. Both
LOX and LOXL were detected in the cultures, but only their
activities, not their expression, were inhibited by BAPN. In
the speciﬁc context of tumor cell differentiation, LOX has
been identiﬁed as the product of the ras recision gene
(rrg)41 whereby up-regulation of LOX gene expression
results in reversion of the ras induced phenotype, while
down-regulation using anti-sense LOX mRNA can be
tumorigenic42. The tumorigenic phenotype is generally,
but not always, associated with a low level of expression of
LOXs13,43e45. In contrast, inhibition of LO activity by BAPN
has never been reported to induce a tumorigenic phenotypein any cell type. This is consistent with a recent report46 that
the anti-tumor effects of LOX are associated with the
propeptide domain of the LOX precursor, independent of
LO activity.
In addition to preventing/delaying the appearance of
collagen I, BAPN appeared to stimulate the production of
cartilage collagens IX and XI. This was observed at the
beginning of the culture period, sometimes before the
production of collagen I, which suggests that it was more
a stimulatory effect than a simple consequence of the drop
in percentage of collagen I resulting in increased percen-
tages of the other collagen types. Such a stimulation in the
production of collagen IX and, more importantly, collagen
XI, compared to the lack of effect on collagen II, particularly
in the cell layer, would probably modify the morphology and
physical properties of the heterotypic collagen II/IX/XI ﬁbrils.
It is well documented1,47 that pure collagen II molecules
form large diameter ﬁbril-like tactoids, quite different from
the normal, small diameter, ﬂexible heterotypic II/IX/XI
ﬁbrils. The low levels of collagens IX and XI produced
when LOX is active could lead to abnormal ﬁbrils which, in
turn, could induce phenotype modulation and de novo
synthesis of collagen I. In this regard, collagen XI has also
recently been reported to limit the diameters of collagen I
ﬁbrils48. In contrast, the presence of BAPN has been shown
to increase collagen ﬁbril diameters in osteoblast cultures49.
This may be a direct consequence of reduced cross-linking
on ﬁbril structure, in the absence of any effects of collagens
IX and XI, which would not be expected to be present in
osteoblast cultures.
Changes in LOX expression have also been linked to
phenotypic changes in other cell types. For example,
down-regulation of LOX occurs prior to retinoic acid
induced differentiation of pre-adipocytes to adipocytes50,
while enhanced secretion of LOX precedes differentiation
of ﬁbroblasts to myoﬁbroblasts in cholestatic ﬁbrosis51. In
both cases, however, the existence of a causal relation-
ship between LO activity and cell differentiation, as
reported here for chondrocytes, was not demonstrated.
In contrast, daily treatment with BAPN has been shown52
to accelerate the recovery of mice after spinal cord injury,
possibly by preventing unwanted modulation of ECM. The
results presented here suggest that this effect might be
due, at least in part, to BAPN induced changes in cell
phenotype. Such effects of LO inhibition on the mainte-
nance of cell phenotype could be envisaged for other cell
types interacting with an extracellular matrix, since this
ubiquitous enzyme is present in practically all solid
tissues.
127Osteoarthritis and Cartilage Vol. 13, No. 2In conclusion, 2D culture with 10% serum could represent
relatively hostile conditions, highly different from those
in situ. In such conditions, active LOXs, essential to produce
normal cartilage, could lead to inappropriate effects. This
latter property could be involved in some processes
occurring in pathological cartilage. LO activity appears to
be involved in the phenotype control of chondrocytes, giving
a novel biological role to the LOX family.
Appendix. Supplementary material
Supplementary material associated with this article can
be found, in the online version, at doi:10.1016/
j.joca.2004.06.015.
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